Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST)

Cancer Letters

Volumn 312, Issue 1, 2011, Pages 43-54

  Daniels, Marc ^a   Lurkin, Irene ^b   Pauli, Roland ^c   Erbstößer, Erhard ^d   Hildebrandt, Uwe ^e   Hellwig, Karsten ^f   Zschille, Uwe ^g   Lüders, Petra ^h   Krüger, Gabriele ⁱ   Knolle, Jürgen ^j   Stengel, Bernd ^k   Prall, Friedrich ^l   Hertel, Kay ^m   Lobeck, Hartmut ⁿ   Popp, Brigitte ^o   Theissig, Franz ^p   Wünsch, Peter ^q   Zwarthoff, Ellen ^b   Agaimy, Abbas ^a   Schneider Stock, Regine ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Klinikum Brandenburg   (Germany)

^d AMEOS Klinikum St Salvator   (Germany)

^e Klinikum Quedlinburg   (Germany)

^f Klinikum Magdeburg   (Germany)

^g Krankenhaus Bautzen   (Germany)

^h NONE   (Germany)

ⁱ Institute of Pathology   (Germany)

^j DESSAU MEDICAL CENTER   (Germany)

^k Institute of Pathology   (Germany)

^l UNIVERSITY OF ROSTOCK   (Germany)

^m HELIOS KLINIKUM ERFURT   (Germany)

ⁿ Ernst von Bergmann Klinikum   (Germany)

^o Practice for Pathology   (Germany)

^p CARL THIEM KLINIKUM   (Germany)

^q KLINIKUM NÜRNBERG   (Germany)

more..

Author keywords

BRAF; Gastrointestinal stromal tumor (GIST); KIT; PI3K; PIK3CA; Platelet derived growth factor receptor alpha (PDGFRA)

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE;

ADULT; AGED; ARTICLE; BRAF GENE; CARCINOGENESIS; CONTROLLED STUDY; EXON; FEMALE; FGFR3 GENE; GENE; GENE DELETION; GENE MUTATION; HRAS GENE; HUMAN; HUMAN TISSUE; KIT GENE; KRAS GENE; MAJOR CLINICAL STUDY; MALE; NRAS GENE; PDGFRA GENE; PIK3CA GENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; DNA MUTATIONAL ANALYSIS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SIGNAL TRANSDUCTION;

EID: 80053308774     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.07.029     Document Type: Article

References (45)

1. Nilsson B., Bumming P., Meis-Kindblom J.M., Oden A., Dortok A., Gustavsson B., Sablinska K., Kindblom L.G. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 2005, 103:821-829.
2. Miettinen M., Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch. Pathol. Lab. Med. 2006, 130:1466-1478.
3. Huizinga J.D. Gastrointestinal peristalsis: joint action of enteric nerves, smooth muscle, and interstitial cells of Cajal. Microsc. Res. Tech. 1999, 47:239-247.
4. Sircar K., Hewlett B.R., Huizinga J.D., Chorneyko K., Berezin I., Riddell R.H. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am. J. Surg. Pathol. 1999, 23:377-389.
5. Miettinen M., Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin. Diagn. Pathol. 2006, 23:70-83.
6. Corless C.L., Fletcher J.A., Heinrich M.C. Biology of gastrointestinal stromal tumors. J. Clin. Oncol. 2004, 22:3813-3825.
7. Martin J., Poveda A., Llombart-Bosch A., Ramos R., Lopez-Guerrero J.A., Garcia del Muro J., Maurel J., Calabuig S., Gutierrez A., Gonzalez de Sande J.L., Martinez J., De Juan A., Lainez N., Losa F., Alija V., Escudero P., Casado A., Garcia P., Blanco R., Buesa J.M. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J. Clin. Oncol. 2005, 23:6190-6198.
8. Lux M.L., Rubin B.P., Biase T.L., Chen C.J., Maclure T., Demetri G., Xiao S., Singer S., Fletcher C.D., Fletcher J.A. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am. J. Pathol. 2000, 156:791-795.
9. Heinrich M.C., Corless C.L., Duensing A., McGreevey L., Chen C.J., Joseph N., Singer S., Griffith D.J., Haley A., Town A., Demetri G.D., Fletcher C.D., Fletcher J.A. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299:708-710.
10. Joensuu H., Roberts P.J., Sarlomo-Rikala M., Andersson L.C., Tervahartiala P., Tuveson D., Silberman S., Capdeville R., Dimitrijevic S., Druker B., Demetri G.D. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. New Engl. J. Med. 2001, 344:1052-1056.
11. Heinrich M.C., Corless C.L., Demetri G.D., Blanke C.D., von Mehren M., Joensuu H., McGreevey L.S., Chen C.J., Van den Abbeele A.D., Druker B.J., Kiese B., Eisenberg B., Roberts P.J., Singer S., Fletcher C.D., Silberman S., Dimitrijevic S., Fletcher J.A. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 2003, 21:4342-4349.
12. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
13. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
14. Agaimy A., Terracciano L.M., Dirnhofer S., Tornillo L., Foerster A., Hartmann A., Bihl M.P. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J. Clin. Pathol. 2009, 62:613-616.
15. Agaram N.P., Wong G.C., Guo T., Maki R.G., Singer S., Dematteo R.P., Besmer P., Antonescu C.R. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosom. Cancer 2008, 47:853-859.
16. Feng Y.Z., Shiozawa T., Miyamoto T., Kashima H., Kurai M., Suzuki A., Konishi I. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression. Clin. Cancer Res. 2005, 11:6133-6138.
17. Hostein I., Faur N., Primois C., Boury F., Denard J., Emile J.F., Bringuier P.P., Scoazec J.Y., Coindre J.M. BRAF mutation status in gastrointestinal stromal tumors. Am. J. Clin. Pathol. 2010, 133:141-148.
18. Blair S.L., Al-Refaie W.B., Wang-Rodriguez J., Behling C., Ali M.W., Moossa A.R. Gastrointestinal stromal tumors express ras oncogene: a potential role for diagnosis and treatment. Arch. Surg. 2005, 140:543-547. (discussion 547-548).
19. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., Velculescu V.E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418:934.
20. Zuiverloon T.C., van der Aa M.N., van der Kwast T.H., Steyerberg E.W., Lingsma H.F., Bangma C.H., Zwarthoff E.C. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin. Cancer Res. 2010, 16:3011-3018.
21. Lurkin I., Stoehr R., Hurst C.D., van Tilborg A.A., Knowles M.A., Hartmann A., Zwarthoff E.C. Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS ONE 2010, 5:e8802.
22. Lasota J., Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008, 53:245-266.
23. Lee J.W., Soung Y.H., Kim S.Y., Lee H.W., Park W.S., Nam S.W., Kim S.H., Lee J.Y., Yoo N.J., Lee S.H. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005, 24:1477-1480.
24. Nicholson K.M., Anderson N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal. 2002, 14:381-395.
25. Platt F.M., Hurst C.D., Taylor C.F., Gregory W.M., Harnden P., Knowles M.A. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin. Cancer Res. 2009, 15:6008-6017.
26. Ramjaun A.R., Downward J. Ras and phosphoinositide 3-kinase: partners in development and tumorigenesis. Cell Cycle 2007, 6:2902-2905.
27. Testa J.R., Bellacosa A. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. USA 2001, 98:10983-10985.
28. Capodanno A., Camerini A., Orlandini C., Baldini E., Resta M.L., Bevilacqua G., Collecchi P. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma. Hum. Pathol. 2009, 40:1408-1417.
29. Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., Kawano K., Hanada M., Kurata A., Takeda M., Muhammad Tunio G., Matsuzawa Y., Kanakura Y., Shinomura Y., Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577-580.
30. Lasota J., Jasinski M., Sarlomo-Rikala M., Miettinen M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am. J. Pathol. 1999, 154:53-60.
31. Taniguchi M., Nishida T., Hirota S., Isozaki K., Ito T., Nomura T., Matsuda H., Kitamura Y. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. 1999, 59:4297-4300.
32. Iesalnieks I., Rummele P., Dietmaier W., Jantsch T., Zulke C., Schlitt H.J., Hofstadter F., Anthuber M. Factors associated with disease progression in patients with gastrointestinal stromal tumors in the pre-imatinib era. Am. J. Clin. Pathol. 2005, 124:740-748.
33. Miettinen M., Sobin L.H., Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am. J. Surg. Pathol. 2005, 29:52-68.
34. Wardelmann E., Losen I., Hans V., Neidt I., Speidel N., Bierhoff E., Heinicke T., Pietsch T., Buttner R., Merkelbach-Bruse S. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int. J. Cancer 2003, 106:887-895.
35. Antonescu C.R., Sommer G., Sarran L., Tschernyavsky S.J., Riedel E., Woodruff J.M., Robson M., Maki R., Brennan M.F., Ladanyi M., DeMatteo R.P., Besmer P. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin. Cancer Res. 2003, 9:3329-3337.
36. Lasota J., Dansonka-Mieszkowska A., Stachura T., Schneider-Stock R., Kallajoki M., Steigen S.E., Sarlomo-Rikala M., Boltze C., Kordek R., Roessner A., Stachura J., Miettinen M. Gastrointestinal stromal tumors with internal tandem duplications in 3' end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod. Pathol. 2003, 16:1257-1264.
37. Lasota J., Wozniak A., Sarlomo-Rikala M., Rys J., Kordek R., Nassar A., Sobin L.H., Miettinen M. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am. J. Pathol. 2000, 157:1091-1095.
38. Lasota J., Kopczynski J., Sarlomo-Rikala M., Schneider-Stock R., Stachura T., Kordek R., Michal M., Boltze C., Roessner A., Stachura J., Miettinen M. KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Hum. Pathol. 2003, 34:1306-1312.
39. Rubin B.P., Singer S., Tsao C., Duensing A., Lux M.L., Ruiz R., Hibbard M.K., Chen C.J., Xiao S., Tuveson D.A., Demetri G.D., Fletcher C.D., Fletcher J.A. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001, 61:8118-8121.
40. Corless C.L., Schroeder A., Griffith D., Town A., McGreevey L., Harrell P., Shiraga S., Bainbridge T., Morich J., Heinrich M.C. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol. 2005, 23:5357-5364.
41. Daum O., Grossmann P., Vanecek T., Sima R., Mukensnabl P., Michal M. Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: molecular genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors. Ann. Diagn. Pathol. 2007, 11:27-33.
42. Lasota J., Dansonka-Mieszkowska A., Sobin L.H., Miettinen M. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab. Invest. 2004, 84:874-883.
43. Penzel R., Aulmann S., Moock M., Schwarzbach M., Rieker R.J., Mechtersheimer G. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated. J. Clin. Pathol. 2005, 58:634-639.
44. Wardelmann E., Hrychyk A., Merkelbach-Bruse S., Pauls K., Goldstein J., Hohenberger P., Losen I., Manegold C., Buttner R., Pietsch T. Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epitheloid or mixed cell morphology in gastrointestinal stromal tumors. J. Mol. Diagn. 2004, 6:197-204.
45. Ogino S., Nosho K., Kirkner G.J., Shima K., Irahara N., Kure S., Chan A.T., Engelman J.A., Kraft P., Cantley L.C., Giovannucci E.L., Fuchs C.S. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J. Clin. Oncol. 2009, 27:1477-1484.